Kim Yeson, Kuan Jen Yee, Ratcliffe Elizabeth, Baskind Samuel, Prasad Neeraj, Assadsangabi Arash, Ang Yeng
Faculty of Biology, Medicine and Health, University of Manchester, Manchester UK.
Gastroenterology Department, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, UK.
Scand J Gastroenterol. 2020 Jan;55(1):18-26. doi: 10.1080/00365521.2019.1707865. Epub 2020 Jan 6.
Endoscopic submucosal dissection (ESD) is extensively performed for the treatment of early gastric cancer (EGC) in the Eastern countries due to its favourable outcomes compared to gastrectomy in terms of lower complication rates, shorter hospital stays, better quality of life, with similar 5-year survival rate. Yet, its use is still limited in the UK. A long-term follow-up study to evaluate the outcome of ESD in the treatment of EGC in a Caucasian population at a tertiary referral centre in the United Kingdom. Data for the 35 Caucasian patients, who underwent ESD in a tertiary referral centre between May 2012 and June 2017 were collected. The selected patients were followed-up until May 2018. Curative resection (CR) and survival rates were used to measure the efficacy of ESD. ESD was attempted on 46 lesions and completed on 37. En-bloc and CR rates of 57% and 19% were achieved, respectively. 24% of the lesions were non-CR and 57% were indefinite for non-CR/CR and 41% of the lesions showed change in histological grade post-ESD. Complete reversal of dysplasia/neoplasia was seen in 60% of the 'indefinite' group and 100% of the CR group at latest FU (18 months, mean). Recurrence was seen in 23% of the patients at latest FU. Seventy-one months' survival rate was 77%, while the disease-specific mortality was 0%. This study demonstrates the positive long-term outcome of ESD for gastric neoplasia in a UK Caucasian population, encouraging further development and implementation of ESD in the UK.
在东方国家,内镜黏膜下剥离术(ESD)因其与胃切除术相比具有并发症发生率更低、住院时间更短、生活质量更高且5年生存率相似等优势,被广泛用于早期胃癌(EGC)的治疗。然而,其在英国的应用仍然有限。一项长期随访研究旨在评估在英国一家三级转诊中心的白种人群中,ESD治疗EGC的效果。收集了2012年5月至2017年6月期间在该三级转诊中心接受ESD治疗的35例白种患者的数据。所选患者随访至2018年5月。采用根治性切除(CR)率和生存率来衡量ESD的疗效。对46个病变尝试进行ESD,其中37个完成。整块切除率和CR率分别达到57%和19%。24%的病变为非CR,57%的病变CR/非CR情况不确定,41%的病变在ESD后组织学分级发生变化。在最新随访(平均18个月)时,60%的“不确定”组和100%的CR组出现发育异常/肿瘤形成完全逆转。在最新随访时,23%的患者出现复发。71个月的生存率为77%,而疾病特异性死亡率为0%。这项研究证明了ESD在英国白种人群中治疗胃肿瘤的积极长期效果,鼓励在英国进一步开展和实施ESD。